Role of Different Brain Structures in the Behavioural Expression of WIN 55,212-2 Withdrawal in Mice

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2004 Jul 22

PMID 15265804

Citations 9

Authors

Anna Castane

Rafael Maldonado

Olga Valverde

Affiliations

Soon will be listed here.

Abstract

We have evaluated several responses induced by the cannabinoid agonist WIN 55,212-2 related to its addictive properties, including rewarding effects and the development of physical dependence in mice. Moreover, we have studied the specific involvement of several brain regions with high density of CB1 cannabinoid receptors, such as striatum, hippocampus, amygdala and cerebellum, in the behavioural expression of SR 141716A-precipitated WIN 55,212-2 withdrawal. The systemic administration of the CB1 receptor antagonist SR 141716A (10 mg kg(-1), s.c.) precipitated behavioural signs of withdrawal in mice chronically treated with WIN 55,212-2 (1 and 2 mg kg(-1), intraperitoneal (i.p.)), revealing the development of physical dependence. The microinjection of SR 141716A (1.5 and 3 micrograms) into the cerebellum induced severe manifestations of abstinence in mice dependent on WIN 55,212-2 (1 mg kg(-1), i.p.). Out of 10 signs evaluated, seven were statistically significant: wet dog shakes, body tremor, paw tremor, piloerection, mastication, genital licks and sniffing. When the cannabinoid antagonist was administered into the hippocampus and the amygdala, a moderate but significant withdrawal syndrome was also observed. However, no signs of abstinence were induced when SR 141716A was microinjected into the striatum. WIN 55,212-2 produced rewarding effects in the place-conditioning paradigm in mice pre-exposed to a priming injection of the drug. These results show a reliable behavioural model to reveal rewarding effects and physical dependence induced by the repeated administration of WIN 55,212-2 in mice. The cerebellum and to a lesser extent the hippocampus and the amygdala participate in the behavioural expression of cannabinoid withdrawal.

Citing Articles

Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.

Myers A, Siegele P, Foss J, Tuma R, Ward S Br J Pharmacol. 2018; 176(10):1552-1567.

PMID: 29338068 PMC: 6487562. DOI: 10.1111/bph.14147.

The Neuroprotective Effect of Lithium in cannabinoid Dependence is Mediated through Modulation of Cyclic AMP, ERK1/2 and GSK-3β Phosphorylation in Cerebellar Granular Neurons of Rat.

Rahimi H, Ghahremani M, Dehpour A, Sharifzadeh M, Ejtemaei-Mehr S, Razmi A Iran J Pharm Res. 2015; 14(4):1123-35.

PMID: 26664379 PMC: 4673940.

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors.

Vinals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de la Torre R PLoS Biol. 2015; 13(7):e1002194.

PMID: 26158621 PMC: 4497644. DOI: 10.1371/journal.pbio.1002194.

Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.

Fanarioti E, Mavrikaki M, Panagis G, Mitsacos A, Nomikos G, Giompres P Int J Neuropsychopharmacol. 2014; 18(6).

PMID: 25522428 PMC: 4438542. DOI: 10.1093/ijnp/pyu097.

Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future.

Panagis G, Mackey B, Vlachou S Front Psychiatry. 2014; 5:92.

PMID: 25132823 PMC: 4117180. DOI: 10.3389/fpsyt.2014.00092.

References

Valjent E, Maldonado R . A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000; 147(4):436-8. DOI: 10.1007/s002130050013. View

Maldonado R . Study of cannabinoid dependence in animals. Pharmacol Ther. 2002; 95(2):153-64. DOI: 10.1016/s0163-7258(02)00254-1. View

Maldonado R, Stinus L, GOLD L, Koob G . Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther. 1992; 261(2):669-77. View

Munro S, Thomas K . Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365(6441):61-5. DOI: 10.1038/365061a0. View

TSOU K, Patrick S, Walker J . Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol. 1995; 280(3):R13-5. DOI: 10.1016/0014-2999(95)00360-w. View

Valverde O, Fournie-Zaluski M, Roques B, Maldonado R . The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology (Berl). 1996; 123(2):119-26. DOI: 10.1007/BF02246168. View

Matthes H, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I . Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996; 383(6603):819-23. DOI: 10.1038/383819a0. View

Ghozland S, Aguado F, Espinosa-Parrilla J, Soriano E, Maldonado R . Spontaneous network activity of cerebellar granule neurons: impairment by in vivo chronic cannabinoid administration. Eur J Neurosci. 2002; 16(4):641-51. DOI: 10.1046/j.1460-9568.2002.02112.x. View

Breivogel C, Scates S, Beletskaya I, Lowery O, Aceto M, Martin B . The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003; 459(2-3):139-50. DOI: 10.1016/s0014-2999(02)02854-6. View

10.

Castane A, Robledo P, Matifas A, Kieffer B, Maldonado R . Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci. 2003; 17(1):155-9. DOI: 10.1046/j.1460-9568.2003.02409.x. View

11.

Derkinderen P, Valjent E, Toutant M, Corvol J, Enslen H, Ledent C . Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci. 2003; 23(6):2371-82. PMC: 6742049. View

12.

Justinova Z, Tanda G, Redhi G, Goldberg S . Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003; 169(2):135-40. DOI: 10.1007/s00213-003-1484-0. View

13.

Piomelli D . The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4(11):873-84. DOI: 10.1038/nrn1247. View

14.

Koob G . Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol. 2003; 13(6):442-52. DOI: 10.1016/j.euroneuro.2003.08.005. View

15.

Takahashi R, Singer G . Self-administration of delta 9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav. 1979; 11(6):737-40. DOI: 10.1016/0091-3057(79)90274-0. View

16.

Herkenham M, Lynn A, Little M, Johnson M, Melvin L, De Costa B . Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990; 87(5):1932-6. PMC: 53598. DOI: 10.1073/pnas.87.5.1932. View

17.

TSOU K, Delay E, Hohman A, Force M, Walker J . Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett. 1997; 223(2):125-8. DOI: 10.1016/s0304-3940(97)13424-3. View

18.

Rodriguez de Fonseca F, Carrera M, Navarro M, Koob G, Weiss F . Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 1997; 276(5321):2050-4. DOI: 10.1126/science.276.5321.2050. View

19.

Maldonado R, Saiardi A, Valverde O, Samad T, Roques B, Borrelli E . Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 1997; 388(6642):586-9. DOI: 10.1038/41567. View

20.

Griffin G, Atkinson P, Showalter V, Martin B, Abood M . Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998; 285(2):553-60. View